PA Capital’s Cidara Therapeutics CDTX Stock Holding History

PA Capital’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-586	Closed	-$20K	–	128
2019 Q2	$20K	Buy	+586	New	+$24.3K	0.02%	107

Other funds holding CDTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PA Capital's CDTX Position: Q3 2019 in Review

PA Capital sold out of Cidara Therapeutics (CDTX) in Q3 2019, closing a stake of 586 shares — an estimated $20K sold.

PA Capital first reported a position in CDTX in Q2 2019 and held it in 1 quarter. The position peaked at $20K in Q2 2019. 39 funds tracked by Wall St. Rank hold CDTX as of Q3 2019.

PA Capital reported no remaining Cidara Therapeutics position as of Q3 2019 after selling out during the quarter.
PA Capital sold 586 Cidara Therapeutics shares in Q3 2019, an estimated $20K.
PA Capital first reported a position in Cidara Therapeutics in Q2 2019 and held it in 1 quarter.
PA Capital's Cidara Therapeutics position peaked at $20K in Q2 2019.
39 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2019.

Based on PA Capital's 13F filing for Q3 2019, filed 8 Nov 2019.